HighGravityDataIncyte — Oct 28, 2025 release
Fiscal 2025 third-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000879169-25-000115
Showing in the filing
Net product revenue
“$4.23 - $4.32 billion”
Period
FY2025
Measure
GAAP-tied
Source
Prose
All guidance in this release · 14
Net product revenue for FY2025
“$4.23 - $4.32 billion”
Jakafi net product revenue for FY2025
“$3.050 - $3.075 billion”
Jakafi for FY2025
“$3.050 - $3.075 billion”
Other hematology and oncology marketed produ… for FY2025
“$550 - $575 million”
Other oncology net product revenues (1) for FY2025
“$550 - $575 million”
Jakafi net product revenues for FY2025
“$3,050 - $3,075 million”
Opzelura ® (ruxolitinib) cream revenue for FY2025
“$630 - $670 million”
Opzelura net product revenues for FY2025
“$630 - $670 million”
GAAP Cost of product revenues for FY2025
“8.0% - 9.0% of net product revenues”
Non-GAAP Cost of product revenues (2) for FY2025
“7.0% - 8.0% of net product revenues”
GAAP Research and development expenses for FY2025
“$1,965 - $1,995 million”
Non-GAAP Research and development expenses (3) for FY2025
“$1,815 - $1,840 million”
GAAP Selling, general and administrative exp… for FY2025
“$1,280 - $1,310 million”
Non-GAAP Selling, general and administrative… for FY2025
“$1,160 - $1,185 million”
Exhibit 99.1 · the passage around this item
… earlier in the release
mpared to the prior year period Hematology-Oncology portfolio net product revenues of $171 million, including Niktimvo ™ (axatilimab-csfr) net revenue of $46 million Raises 2025 full year net product revenue guidance to $4.23 - $4.32 billion Conference Call and Webcast Scheduled Today at 8:00 a.m. ET WILMINGTON, Del. – October 28, 2025 – Incyte (Nasdaq:INCY) today reported financial results for the third quarter of 2025 and provided a business update. “Our third-quarter results demonstrate strong growth across our product portfolio, with net product revenues increasing 19% year-over-year, which highlights the momentum in our business and effective commercial execution,” said Bill Meury, President and Chief Executive Officer, Incyte. “We are taking a deliberate approach to pipeline prioritization. We are actively reviewing our R&D efforts and focusing on high-value programs that are scientifically differentiated, address unmet medical needs, and have the potential to significantly drive Incyte’s next phase of growth." Third Quarter 2025 Results • Total revenues: Total revenues were $1.37 billion, an increase of 20% compared to the third quarter of 2024, primarily driven by an increase in total net product revenues. Total net product revenue for the third quarter of 2025 was $1.15 billion, an increase of 19%. The increase was primarily related to patient demand for Jakafi ® (ruxolitinib) across all indications and stron
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.